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Background: Literature on the timing of rabbit antithymocyte globulin (rATG) induction and its effects on kidney
transplant outcomes is limited. The manufacturer recommends that the first dose be given intra-operatively,
however this may present clinical practice risks and challenges. Our objective was to assess the impact of the timing
of the first dose of rATG on kidney transplant outcomes.
Methods: Incident kidney transplant recipients (KTR) from January 2002 to December 2009 receiving the first dose
of rATG post-operatively (Post, n = 353) or before reperfusion (Pre, n = 124) were evaluated. Outcomes assessed
included eGFR at 1-year, delta eGFR (12 versus 1 month), and incidence of biopsy-proven acute rejection, graft loss,
death, and a composite of the time-to-event outcomes. The impact of timing on outcomes was adjusted for
potential confounders and assessed using linear and Cox regression models.
Results: Among 435 KTR surviving with function to 12 months post-transplant, there was no significant difference
in mean estimated glomerular filtration rate or eGFR (55.0 versus 56.7 mL/min, P = 0.46) and delta eGFR (1.8 versus
0.3 mL/min, P = 0.40) in Post versus Pre groups, respectively. At a median follow-up of 3 years, the composite
endpoint (time to first biopsy-proven acute rejection, graft loss, or death) was similar by timing group (adjusted
HR = 0.94; 95% CI: 0.58, 1.53, P = 0.81) in the total study population.
Conclusions: Timing of rATG had no appreciable impact on clinically relevant endpoints in this study cohort. These
results support consideration of more flexible timing of the first dose of rATG induction in KTR.
Keywords: Induction therapy, Kidney transplantation, Outcomes, Cohort studyBackground
Rabbit antithymocyte globulin (rATG, Thymoglobulin™,
Genzyme Canada Inc., Mississauga, ON, Canada) is a
polyclonal gamma immunoglobulin derived from the
immunization of rabbits with human thymocytes and in-
dicated for the prevention and treatment of acute kidney
transplant rejection [1]. Induction with rATG, together
with maintenance immunosuppression (that is, calcine-
urin inhibitor, anti-metabolite, and corticosteroids), has
been shown to be more effective than maintenance im-
munosuppression alone in preventing episodes of acute
rejection in adult kidney transplant recipients (KTR)* Correspondence: joseph.kim@uhn.ca
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reproduction in any medium, provided the or[2,3]. However, adverse events such as fever, chills and
gastrointestinal distress are more frequent with rATG
than with other induction agents [4,5]. Serious reactions
such as cytokine release syndrome with hemodynamic
instability can also occur and are most commonly asso-
ciated with the first dose and rapid infusion rates [1].
The question of timing of first dose of rATG induc-
tion is relevant in clinical practice since operational
factors may favor postoperative administration. The
manufacturer advises intra-operative dosing, a recom-
mendation supported by one randomized controlled
trial in which intra-operative dosing led to a reduction
in delayed graft function (DGF) and lower serum cre-
atinine at 14 days post-transplant when compared to
postoperative dosing [6]. However, adverse drug events
resulting from medication error occur commonly in thel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ity and mortality [7].
The operating room environment, with its multiple di-
versions and production pressures, dynamic changes in
patient physiology, and the potential for provider fatigue,
all contribute to this safety risk [7]. For this reason, we
have implemented a practice change at our center in re-
cent years to begin administration of induction therapy
in the immediate postoperative period. There is a pau-
city of published data to support this approach and little
is known about the impact of timing of the initial dose
on long-term outcomes.
The primary objective of this study was to compare
renal function at one year in KTR receiving the first dose
of rATG postoperatively versus prior to graft reperfu-
sion. The secondary objective was to compare the risk of
achieving the composite endpoint of biopsy-proven
acute rejection (BPAR), graft loss, or death across induc-
tion timing groups.
Patients and methods
Study design and population
We conducted a single-center observational cohort
study of all de novo KTR receiving rATG induction
therapy from 1 January 2002 to 31 December 2009 with
follow-up until 31 December 2010. We included all pa-
tients receiving at least one dose of rATG for the pur-
pose of induction within 7 days of transplantation.
Patients who received a partial course of another in-
duction agent (for example, basiliximab) were included.
Excluded from the analysis were multi-organ transplant
recipients, cases of primary nonfunction, and patients
undergoing desensitization protocols.
Standard maintenance immunosuppression during the
study period included a calcineurin inhibitor, mycopheno-
late mofetil, and prednisone. Until 2005, the first-line cal-
cineurin inhibitor was cyclosporine microemulsion, with
C2 level monitoring to a target of 1,700 ng/mL post-
transplant. Subsequently, tacrolimus became the standard
calcineurin inhibitor with trough level monitoring to a tar-
get of 10 to 15 ng/mL or 5 to 8 ng/mL for high and low
immunologic risk patients, respectively. Some patients at
high risk of developing new-onset diabetes mellitus were
initiated on cyclosporine microemulsion. Since 2005, the
initial C2 target for cyclosporine microemulsion has been
modified to 1,000 to 1,200 ng/mL. Standard steroid ther-
apy included a pre-operative dose of intravenous methyl-
prednisolone 1 mg/kg followed by an oral prednisone
taper. Prior to 2006, patients received a slow prednisone
taper to 5 mg per day over the first 3 months. Since 2006,
all patients at low immunologic risk receive a rapid pred-
nisone taper to 5 mg per day by postoperative day 7. My-
cophenolate mofetil was used at a dose of 1 g orally twice
daily starting immediately post-transplant. The dosingregimen was adjusted to 500 mg orally four times daily for
patients experiencing adverse gastrointestinal effects. For
refractory symptoms the dose of mycophenolate mofetil
was reduced at the discretion of the treating physician.
Acute rejections were treated with intravenous corti-
costeroids, rATG, intravenous immunoglobulin, and/or
plasmapheresis (the latter two treatments for acute
antibody-mediated rejection). Rituximab was also used
in cases of refractory acute antibody-mediated rejection.
Biopsies were performed for indication and reviewed by
a renal pathologist using the Banff classification.
Exposure and outcome assessment
Patients were grouped according to the timing of the
first dose of rATG. Those who received the first dose
prior to graft reperfusion (pre- or intra-operatively)
were included in the ‘Pre’ group. Patients receiving the
first dose of rATG postoperatively were included in the
‘Post’ group.
The primary outcome was the eGFR using the Chronic
Kidney Disease Epidemiology Collaboration estimated
glomerular filtration rate (CKD-EPI) equation at one
year post-transplant [8]. The secondary outcome was
the composite endpoint of BPAR, graft loss, or death. All
forms of acute rejection (T cell-mediated and antibody-
mediated) were included in the composite endpoint. Graft
loss was defined as the need to return to chronic dialysis
or pre-emptive re-transplant. All deaths occurred prior to
graft loss.
Potential confounders
Recipient, donor, and transplant characteristics, as well
as the indication for rATG induction, total rATG dose,
starting time of rATG infusion and duration of therapy,
were collected through a review of medical charts and
our center’s Comprehensive Renal Transplant Research
Information System (CoReTRIS) database. Recipient
characteristics included age, sex, race, cause of end-stage
renal disease (ESRD), body mass index, peak panel react-
ive antibody (PRA) level, time on dialysis, and re-graft
status. Donor characteristics included donor type (de-
ceased versus living), age, sex, and body mass index.
Along with induction therapy, transplant characteristics
included maintenance immunotherapy, occurrence of
DGF (defined as the need for at least one dialysis session
within the first week post-transplant) and transplant era
(grouped as 2002 to 2004, 2005 to 2007, and 2008 to
2009). All of the above variables were included as poten-
tial confounders in our statistical models.
Total rATG dose (adjusted for weight) and indication
for induction were also included in all statistical models.
Indication categories included high-risk recipient and
donor, high-risk recipient, high-risk donor, and low-risk
recipient and donor. Categorization was based on the
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in the medical chart. In addition, recipients were classi-
fied as high-risk if any of the following were noted: peak
PRA greater than 10%, presence of known donor-
specific antibody, or re-graft status. Donors were consid-
ered high-risk if they were expanded criteria (ECD) or
donation after cardiac death (DCD).
Statistical analysis
Standard baseline characteristics were compared using
parametric (unpaired t-test or one-way analysis of vari-
ance (ANOVA)) and non-parametric (Mann-Whitney U
test or Kruskal-Wallis test) for continuous variables as
appropriate. Proportions were compared using the Fish-
er’s exact or the chi-square tests. The association of tim-
ing and CKD-EPI eGFR at 12 months was evaluated
while simultaneously accounting for confounding vari-
ables using multiple linear regression models. Changes
in eGFR from month 1 to month 12 were also calculated
in order to relate the induction timing strategy to the
trajectory of eGFR over the first year post-transplant.
Time to the composite endpoint of first BPAR, graft
failure, or death was examined using multivariable Cox
proportional hazards models. The individual compo-
nents of the composite endpoint were also evaluated
separately. The timing of induction therapy was intro-
duced as an indicator variable with the pre/intra-opera-
tive dosing strategy serving as the referent group. Other
recipient, donor, and transplant covariates were intro-
duced to adjust for potential confounding. An inter-
action term was used in our fully adjusted models to
determine if donor type significantly modified the asso-
ciation between induction timing and each of the out-
comes studied. The assumption of proportionality was
graphically examined using log (cumulative hazard) plots
and scaled Schöenfeld residuals. No important violations
of the proportionality assumption were identified.
All analyses were performed using Stata/MP 11.2 (Col-
lege Station, TX, USA). A two-sided P value of <0.05
was considered statistically significant. Approval for the
study was obtained through the Research Ethics Board
of the University Health Network.
Results
A total of 555 KTR received induction therapy with rATG
during the 8-year study period. From this cohort, 78 pa-
tients were excluded (38 in desensitization protocols, 21
multiple organ recipients, 14 with primary nonfunction,
and 5 lacking follow-up data). Of the 477 remaining pa-
tients, 124 (26%) had rATG induction initiated prior to
graft re-perfusion (Pre), while 353 (74%) started rATG
post-operatively (Post). Overall, the median time to begin-
ning the rATG infusion in the Post group was 7.3 hours
from the time of leaving the operating room (interquartilerange 5.4 to 15.1 hours; n = 268 observations). Median time
to starting rATG was greater for those who developed
DGF (n = 74) compared to those who did not (n = 194)
(9.2 versus 6.6 hours respectively, P < 0.001).
Baseline characteristics were similar between groups
and most potential confounders were equally distributed
(Table 1). Patients in the Post group were more likely to
be older, receive a deceased donor transplant, have a
shorter cold ischemia time, have a longer length of hos-
pital stay and experience DGF. A significant era effect
was observed with more patients receiving the first dose
of rATG post-operatively in the later era. Patients in the
Post group were also more likely to be on a tacrolimus-
based regimen. There were no statistically significant dif-
ferences between the groups in the other variables that
were assessed.
Table 2 displays the indications for induction therapy
and specific treatment characteristics. The most com-
mon indication for rATG in the Pre group was high-risk
recipient (53.2%), whereas in the Post group it was low-
risk recipient with a low-risk donor (40.2%). The mean
total and weight-adjusted dose of rATG was significantly
higher in the Pre group. The total number of doses ad-
ministered was similar between the two groups.
Thirteen and 29 patients were excluded from the pri-
mary endpoint analysis in the Pre and Post groups re-
spectively due to graft loss, death with function, or
loss to follow-up within the first year. Timing of the
first dose of rATG failed to demonstrate a statistically
significant association with the CKD-EPI eGFR at 12-
months (mean CKD-EPI eGFR of 55.0 ± 21.1 versus
56.7 ± 18.2 mL/min in the Post versus Pre groups,
P = 0.46). Results from the multiple linear regression
model are shown in Table 3. When adjusted for recipi-
ent, donor, and transplant covariates, the difference
between the groups remained small (β = 0.64 (95% CI:
-2.82, 4.11), P = 0.72). This difference remained similarly
non-significant when renal function was assessed using
the four-variable MDRD (Modification of Diet in Renal
Disease) eGFR equation and after adjustment for the
type of calcineurin inhibitor, the use of corticosteroid
withdrawal regimens, or for patients receiving only one
dose of basiliximab.
The difference in eGFR (that is, delta eGFR) from 1 to
12 months was similar across the groups (1.8 ± 16.4 versus
0.3 ± 17.2 mL/min for Post versus Pre groups, P = 0.40). In
the adjusted model, the difference in delta eGFR for the
Post versus Pre groups was not statistically significant (β =
1.77 (95% CI: -2.08, 5.63), P = 0.37) (Table 3).
Inclusion of an interaction term in our fully adjusted
models revealed that donor type did not significantly
modify the association between rATG timing and
eGFR (12 months) and delta eGFR (1 to 12 months)
(data not shown).
Table 1 Recipient, donor, and transplant characteristics
Baseline characteristics Total (n = 477) Pre (n = 124) Post (n = 353) P value
Recipient characteristics
Mean recipient age (years) 477 48.5 ± 13.3a 51.3 ± 13.1 0.04
Recipient sex
0.14Male 296 70 (56.5%) 226 (64.0%)
Female 181 54 (43.6%) 127 (36.0%)
Race
0.19Caucasian 289 69 (55.7%) 220 (62.3%)
Non-Caucasian 188 55 (44.4%) 133 (37.7%)
Mean height (cm) 477 167.9 ± 11.9 168.1 ± 9.9 0.83
Mean weight (kg) 477 77.7 ± 18.1 75.1 ± 16.3 0.13
Body mass index (kg/m2) 477 27.6 ± 5.8 26.5 ± 5.2 0.07
Cause of ESRD
0.58
Diabetes 83 17 (13.7%) 66 (18.7%)
Glomerulonephritis 171 51 (41.1%) 120 (34.0%)
Polycystic kidney disease 55 15 (12.1%) 40 (11.3%)
Hypertension 48 12 (9.7%) 36 (10.2%)
Other 120 29 (23.4%) 91 (25.8%)
Transplant number
0.57First graft 396 105 (84.7%) 291 (82.4%)
Re-graft 81 19 (15.3%) 62 (17.6%)
Median PRA (%)b 477 15 (0,49) 10 (0,46) 0.23
Median length of stay (days)b 477 9 (7,12) 11 (8,16) 0.01
Donor characteristics
Mean donor age (years) 477 45.8 ± 13.9 48.5 ± 14.2 0.05
Donor sex
1.00Male 250 65 (52.4%) 185 (52.4%)
Female 227 59 (47.8%) 168 (47.6%)
Median donor CrCl (mL/min)b, c 445 (117/328)d 110.6 (92.9, 137.6) 110.5 (91.5, 140.9) 0.88
Mean CIT (min)e 244 (38/206)d 954.7 ± 314.7 810.7 ± 375.2 0.03
Donor type (%)
0.002Deceased 312 67 (54.0%) 245 (69.4%)
Living 165 57 (46.0%) 108 (30.6%)
DCD kidneys
No 443 124 (100%) 319 (90.4%) <0.001




2002 to 2004 86 31 (25.0%) 55 (15.6%)
2005 to 2007 186 61 (49.2%) 125 (35.4%)
2008 to 2009 205 32 (25.8%) 173 (49.0%)
Delayed graft function
No 332 99 (79.8%) 233 (66.0%) 0.004
Yes 145 25 (20.2%) 120 (34.0%)
Maintenance CNI < 0.001
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Table 1 Recipient, donor, and transplant characteristics (Continued)
Tacrolimus 360 78 (62.9%) 282 (79.9%)
Cyclosporine 106 45 (36.3%) 61 (17.3%)
CNI-free 11 1 (0.8%) 10 (2.8%)
CIT, cold ischemia time; CNI, calcineurin inhibitor; CrCl, creatinine clearance; DCD, donation after cardiac death; ESRD, end stage renal disease; PRA, panel
reactive antibodies.
aPlus-minus values are means ± standard deviation.
bMedian (interquartile range).
cCreatinine clearance estimated using the Cockcroft-Gault formula.
dTotal number assessed (Pre group/Post group).
eDeceased donor kidney transplants only.
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The median follow-up time was 3.0 years (interquartile
range 1.6 years to 4.9 years). This constituted a total of
1200.1 person-years at risk for the composite outcome.
There was no significant difference in time to first
BPAR, graft loss, death or the composite across treat-
ment groups as depicted by the Kaplan-Meier failure
functions in Figure 1. These findings were confirmed in
the multivariable Cox proportional hazards model after
adjustment for potential confounders (Table 4). The ad-
justed hazard ratio for the composite endpoint was 0.94
(95% CI: 0.58, 1.53; P = 0.81). Inclusion of an interaction
term for timing of induction and donor type in our fully
adjusted model showed that donor type did not signifi-
cantly modify the association between timing of induc-
tion and the outcomes of first BPAR, graft loss, death, or
the composite (P values for interaction = 0.61, 0.27, 0.48,
0.69, respectively). Moreover, adjustment for the type of
calcineurin inhibitor at hospital discharge or estimating
the treatment effect in a propensity score matched sub-
cohort (85 Pre/Intra versus 85 Post) corroborated the
null association of timing and the study outcomes ob-
served in the primary analysis (data not shown).
Discussion
Timing of the first dose of rATG induction prior to graft
reperfusion had no significant impact on renal function at
one year when compared to post-operative administrationTable 2 rATG indication and treatment characteristics
Pre (n =
Indication for rATG
High risk recipient and donor 3 (2.4
High risk recipient 66 (53
High risk donor 16 (12
Low risk recipient and donor 39 (31
Mean total dose rATG (mg) 467.7 ±
Mean total weight-adjusted dose rATG (mg/kg) 6.0 ±
Median number rATG dosesb 5 (4
rATG, rabbit antithymocyte globulin.
aPlus-minus values are means ± standard deviation.
bMedian (interquartile range).in this retrospective cohort study of adult KTR. In both
the unadjusted and adjusted linear regression models, this
difference remained nonsignificant. The CKD-EPI equa-
tion was used to estimate renal function as it has recently
been shown to offer better performance when compared
to the MDRD study equation in KTR [8]. Furthermore,
postoperative administration of rATG induction had no
discernable effect on time to first BPAR, graft loss, death
or the composite when evaluated over the 5-year follow-
up period. These findings were confirmed in multivariable
Cox regression models.
Notably, patients in the Post group were more likely
to be older, recipients of deceased donor organs, trans-
planted later in the study period, and had longer lengths
of stay in hospital. This is a reflection of time trends in
the population transplanted at our center, with recipi-
ents of greater medical complexity and an increasing use
of ECD and DCD donor organs in the more recent era.
Lower dosing of rATG in the Post group reflects prac-
tice changes over time. In 2007, we instituted a new im-
munosuppression protocol for low-risk patients that
included low dose rATG (3 mg/kg) for induction. In re-
cent years there has also been a trend towards reducing
the total dose of rATG induction for high-risk patients.
However, when controlling for these variables in the
adjusted model we observed no difference in outcome
by the two timing strategies. In fact, the higher preva-






157.5a 379.5 ± 160.0 < 0.0001
1.4 5.1 ± 2.0 < 0.0001
, 6) 5 (4, 6) 0.17
Table 3 Linear regression models for mean CKD-EPI eGFR at 12 months and mean delta CKD-EPI eGFR at 1 versus 12
months
Models Mean CKD-EPI eGFRa beta coefficient for timing (95% CI) Mean delta CKD-EPI eGFRa beta coefficient for timing (95% CI)
1 −1.67 (−6.07, 2.74) 1.52 (−2.06, 5.10)
2 −0.67 (−5.11, 3.77) 0.97 (−2.69, 4.63)
3 1.14 (−2.36, 4.64) 1.62 (−2.16, 5.41)
4 0.88 (−2.51, 4.27) 1.46 (−2.31, 5.23)
5 0.64 (−2.82, 4.11) 1.77 (−2.08, 5.63)
Model 1 = Timing only.
Model 2 =Model 1 + indication (high risk recipient and donor, high risk recipient, high risk donor, low risk recipient and donor).
Model 3 =Model 2 + 1-month recipient eGFR (CKD-EPI) + weight-adjusted total rATG dose + recipient sex + recipient BMI + recipient age + recipient race
(Caucasian or non-Caucasian) + cause of ESRD (diabetes or non-diabetes) + time on dialysis + peak PRA + re-graft status.
Model 4 =Model 3 + donor age + donor sex + donor type (living or deceased).
Model 5 =Model 4 + transplant era + occurrence of DGF.
BMI, body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DGF, delayed graft function; eGFR, estimated glomerular filtration rate; ESRD,
end stage renal disease; PRA, panel reactive antibodies; rATG, rabbit antithymocyte globulin.
ain mL/min.
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residual confounding bias would lead to worse out-
comes for the Post group. This increases the robustness
of our inferences.
A number of studies have shown the efficacy of postop-
erative rATG induction in reducing acute rejection rates
[2-4], however others have suggested that intra-operative
infusion may be preferable [5,9-12]. In a prospective,Figure 1 Kaplan-Meier curves for time to biopsy-proven acute rejecti
endpoint by the rATG timing group.randomized, controlled trial of intra-operative versus post-
operative rATG among 58 KTR, Goggins et al. demon-
strated that the incidence of DGF is reduced with adminis-
tration prior to cross-clamp removal [6]. Ischemia has
been shown to cause endothelial activation and promotion
of leukocyte adhesion and trafficking into the allograft,
which in turn leads to expression of co-stimulatory mole-
cules, cytokine release, and lymphocyte activation [13].on, graft loss, death with graft function, and the composite
Table 4 Cox model for biopsy-proven acute rejection, graft loss and death (n = 477) over 5-year follow-up
Number of eventsa Pre (n = 124)b Post (n = 353)b Hazard Ratio (95% CI)c P value
BPAR 68 (19/49) 17.6% 15.5% 0.90 (0.50, 1.64) 0.73
Graft loss 29 (8/21) 8.6% 10.1% 1.04 (0.41, 2.61) 0.94
Death 26 (10/16) 9.8% 6.3% 0.54 (0.21, 1.39) 0.20
Composite 103 (29/74) 27.0% 25.7% 0.94 (0.58, 1.53) 0.81
aTotal number of events (Pre group/Post group).
bCumulative probability of the outcome at 5-years using the Kaplan-Meier product limit method.
cPredictors in the Cox model include: timing of induction, indication (high risk recipient and donor, high immunologic risk recipient, high risk donor and low
immunologic risk recipient), occurrence of DGF, weight-adjusted total rATG dose, recipient age, recipient sex, recipient race (Caucasian or non-Caucasian), cause of
ESRD (diabetes or non-diabetes), time on dialysis, peak PRA, re-graft status, recipient BMI, donor age, donor sex, donor type (living or deceased), and transplant
era (2002 to 2004, 2005 to 2007 and 2008 to 2009).
BMI, body mass index; BPAR, biopsy-proven acute rejection; CI, confidence interval; DGF, delayed graft function; ESRD, end stage renal disease; PRA, panel reactive
antibodies; rATG, rabbit antithymocyte globulin.
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ischemic-reperfusion injury mediators, it may act to at-
tenuate this response [14,15]. While the intra-operative
group had a lower mean serum creatinine at 14 days post-
transplant, this early difference in renal function was not
statistically significant by day 30 [6].
From a practice standpoint, operational factors favor
postoperative administration of rATG. Preparation of
this drug involves dose calculation, reconstitution of
multiple medication vials, dilution in an appropriate vol-
ume, and limited stability that precludes advance admix-
ing. Pre-medication is required, and the infusion must
be run through a high-flow vein using an inline filter
over a minimum of 6 hours with close monitoring [1].
While some centers have been able to address these is-
sues through strategies such as order sets, protocols,
education, and involvement of the clinical pharmacist,
time between patient arrival and transfer to the operat-
ing room is often insufficient to allow for pre-operative
dosing and physical transport of the patient with rATG
infusing may present a challenge.
Intra-operative dosing also introduces safety risks such
as erroneous administration technique, which has con-
sistently been one of the most harmful types of medica-
tion errors in health systems reporting [16]. The typical
process for medication administration in the operating
room is dramatically abbreviated and lacks the usual
safeguards that exist in other areas of the hospital [7]. In
a Canadian survey of 687 anesthesiologists, 85% report a
drug error or a near miss in clinical practice [17]. In a
New Zealand study, 12.5% of practitioners surveyed re-
ported that they were aware of harm caused to a patient
as a result of a drug administration error [18]. In mid-
2007, computerized prescriber order entry was instituted
on the inpatient wards at our hospital. This change in-
troduced further complexities to the peri-operative
workflow since the operating room retained a paper-
based process. Due to the occurrence of a number of se-
vere intra-operative medication errors involving rATG, apractice change was instituted in late 2007 to have rATG
administered in the immediate post-operative setting.
This allowed for management by experienced staff, sim-
plified workflow, and has since eliminated serious medi-
cation errors associated with rATG at our center.
While intra-operative administration of rATG may
have a favorable impact on short-term outcomes, there
is limited literature to show that a benefit is maintained
over time. Such short-term outcomes are certainly rele-
vant, however induction therapy may also have more
durable effects that are important to examine. Potential
long-term benefits of rATG induction may include im-
proved graft survival by decreasing acute rejection rates
and limiting exposure to calcineurin inhibitors in the
early post-transplant period. In our study, we observed
no differences by timing of rATG induction on clinically
meaningful endpoints including eGFR, BPAR, graft loss,
or death over the follow-up period.
Our study addresses a clear gap in the literature. The
single previous report evaluating timing of rATG induc-
tion in KTR involved a small number of patients with a
follow-up period of only 30 days. With the shift in clin-
ical practice at our institution we had a unique oppor-
tunity to examine the impact of rATG induction timing.
The present study is the largest to date and has a me-
dian duration of follow-up of 3 years. The use of multi-
variable regression modeling to adjust for potential
confounders strengthens our analysis of timing of induc-
tion therapy as it relates to meaningful clinical end-
points. Despite the shift in the later era towards post-
operative administration, there remained a significant
degree of overlap between pre- versus post-operative ad-
ministration during the 8-year study period, with good
representation of both high and low risk patients in both
Pre and Post groups across all transplant eras.
There are limitations to our study that deserve men-
tion. First, this was not a randomized controlled trial,
and therefore the possibility of residual confounding ex-
ists. To reduce this risk, data were retrieved through a
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priori, and multivariable modeling was used to account
for differences in baseline characteristics between the
groups. Moreover, an assessment of the effectiveness
(versus efficacy) of rATG timing in the real world setting
is best estimated using a clinical cohort. Second, there
may have been a selection bias related to timing since,
following implementation of the practice change, 23%
of patients in the later era still received rATG pre-
operatively. It is possible that some of these cases may
have had higher risk features that were not captured in
our baseline analysis and may have been pre-disposed to
worse outcomes. Notably, it is routine practice in our
center to admit patients for living donor kidney trans-
plantation on the night before surgery which allows ad-
equate time for pre-operative rATG administration. This
likely accounts for the majority of patients in the Pre
group in the later era. Third, since rATG was often pre-
scribed in response to the development of DGF post-
operatively, it was not possible to analyze the impact of
rATG timing on the incidence of DGF without signifi-
cant confounding by indication. However, the occur-
rence of DGF in the early postoperative period was
included as a confounder in our statistical models.
Fourth, because this study was conducted in a single in-
stitution, the findings may not be entirely generalizable
to other settings. Finally, although this is the largest
study to date on the issue of induction timing and kid-
ney transplant outcomes, it may have been underpow-
ered to rule out small treatment effects.
Conclusions
The results of this retrospective cohort study of KTR
suggest that pre/intra-operative versus postoperative
administration of rATG induction has similar implica-
tions for renal function at one year post-transplant.
Moreover, the risk of developing clinically relevant end-
points over a 5-year follow-up period was comparable
across rATG timing groups. While our results do not
definitively rule out a small but meaningful benefit of
pre/intra-operative administration of rATG, we believe
our findings open the door to explore more flexible tim-
ing strategies for the first dose of rATG induction ther-
apy in kidney transplantation.
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